KOBLIZEK, Vladimir, Branislava MILENKOVIC, Michal SVOBODA, Jana KOCIANOVA, Stanislav HOLUB, Vladimir ZINDR, Miroslav ILIC, Jelena JANKOVIC, Vojislav CUPURDIJA, Jiří JARKOVSKÝ, Boris POPOV and Arschang VALIPOUR. RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD. International Journal of chronic obstructive pulmonary disease. Albany: Dove Medical Press Ltd., 2023, vol. 18, November 2023, p. 2661-2672. ISSN 1178-2005. Available from: https://dx.doi.org/10.2147/COPD.S426919.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD
Authors KOBLIZEK, Vladimir (203 Czech Republic), Branislava MILENKOVIC (203 Czech Republic), Michal SVOBODA (203 Czech Republic, belonging to the institution), Jana KOCIANOVA (203 Czech Republic), Stanislav HOLUB (203 Czech Republic), Vladimir ZINDR (203 Czech Republic), Miroslav ILIC (203 Czech Republic), Jelena JANKOVIC (203 Czech Republic), Vojislav CUPURDIJA, Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Boris POPOV and Arschang VALIPOUR.
Edition International Journal of chronic obstructive pulmonary disease, Albany, Dove Medical Press Ltd. 2023, 1178-2005.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30203 Respiratory systems
Country of publisher New Zealand
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.800 in 2022
RIV identification code RIV/00216224:14110/23:00133349
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.2147/COPD.S426919
UT WoS 001109137500001
Keywords in English COPD; survival; mortality; Central and Eastern Europe; respiratory; clinical phenotype; cluster
Tags 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 31/1/2024 12:38.
Abstract
Purpose: The Phenotypes of COPD in Central and Eastern Europe (POPE) study assessed the prevalence and clinical characteristics of four clinical COPD phenotypes, but not mortality. This retrospective analysis of the POPE study (RETRO-POPE) investigated the relationship between all-cause mortality and patient characteristics using two grouping methods: clinical phenotyping (as in POPE) and Burgel clustering, to better identify high-risk patients.Patients and Methods: The two largest POPE study patient cohorts (Czech Republic and Serbia) were categorized into one of four clinical phenotypes (acute exacerbators [with/without chronic bronchitis], non-exacerbators, asthma-COPD overlap), and one of five Burgel clusters based on comorbidities, lung function, age, body mass index (BMI) and dyspnea (very severe comorbid, very severe respiratory, moderate-to-severe respiratory, moderate-to-severe comorbid/obese, and mild respiratory). Patients were followed-up for approximately 7 years for survival status.Results: Overall, 801 of 1,003 screened patients had sufficient data for analysis. Of these, 440 patients (54.9%) were alive and 361 (45.1%) had died at the end of follow-up. Analysis of survival by clinical phenotype showed no significant differences between the phenotypes (P=0.211). However, Burgel clustering demonstrated significant differences in survival between clusters (P<0.001), with patients in the "very severe comorbid" and "very severe respiratory" clusters most likely to die. Overall survival was not significantly different between Serbia and the Czech Republic after adjustment for age, BMI, comorbidities and forced expiratory volume in 1 second (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.65-0.99; P=0.036 [unadjusted]; HR 0.88, 95% CI 0.7-1.1; P=0.257 [adjusted]). The most common causes of death were respiratory-related (36.8%), followed by cardiovascular (25.2%) then neoplasm (15.2%).Conclusion: Patient clusters based on comorbidities, lung function, age, BMI and dyspnea were more likely to show differences in COPD mortality risk than phenotypes defined by exacerbation history and presence/absence of chronic bronchitis and/or asthmatic features.
PrintDisplayed: 10/6/2024 10:03